2 citations
,
October 2021 in “Exploration of targeted anti-tumor therapy” This review describes oncotherapy-induced alopecia in patients receiving hormone therapy for hormone-receptor-positive breast cancer and concludes that topical hormones should not be used due to oncogenic potential.
December 2022 in “Journal of The American Academy of Dermatology” This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.
May 2022 in “Annals of Oncology” This study found that photobiomodulation may accelerate hair regrowth one month after chemotherapy in breast cancer patients, but no significant differences were observed at two and three months post-therapy.
November 2025 in “Molecular and Cellular Biomedical Sciences” This study evaluated the effects of exosome therapy from hypoxia-treated mesenchymal stem cells on a fluconazole-induced alopecia model in rats and found that it significantly reduced TNF-α and increased VEGF levels, suggesting potential as a novel regenerative treatment for alopecia.
December 2023 in “Trials” In this randomized controlled trial involving breast cancer patients undergoing chemotherapy, this study investigated the efficacy of low-level light therapy for preventing hair loss, measuring outcomes like hair count and patient quality of life, but the abstract does not report specific results.
